Vagal Stimulation Ameliorates Non-Alcoholic Fatty Liver Disease in Rats

• Published in: Biomedicines 2023-12, Vol.11 (12), p.3255
• Main Authors: Elkattawy, Hany A, Mahmoud, Samar Mortada, Hassan, Ahmed El-Sayed, Behiry, Ahmed, Ebrahim, Hasnaa Ali, Ibrahim, Ateya Megahed, Zaghamir, Donia Elsaid Fathi, El-Sherbiny, Mohamed, El-Sayed, Sherein F
• Format: Article
• Language: English
• Subjects: Abdomen; Albumin; Body mass index; Carbohydrates; Caspase-3; Cholesterol; Diabetes; Diabetes mellitus; Diabetes therapy; Diet; Electrodes; Fatty acids; Fatty liver; Glucose; Health aspects; High fat diet; Immunohistochemistry; Inflammation; Insulin resistance; Liver; Liver diseases; Medical research; Metabolism; non-alcoholic fatty liver; Obesity; Oxidative stress; Physiological aspects; Public health; Steatosis; Triglycerides; Tumor necrosis factor-α; Vagus nerve; Weight control
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11123255

The harmful consequences of non-alcoholic fatty liver disease (NAFLD) are posing an increasing threat to public health as the incidence of diabetes and obesity increases globally. A non-invasive treatment with a range of autonomic and metabolic benefits is transcutaneous vagus nerve stimulation (tVNS). To investigate the possible preventive impacts of VNS against adult rats' NAFLD caused by a high-fat diet (HFD) and to clarify the underlying mechanisms. A total of thirty-two adult male rats were split into two groups: the HFD-induced NAFLD group ( = 24) and the control normal group ( = 8). The obesogenic diet was maintained for 12 weeks to induce hepatic steatosis. The HFD-induced NAFLD group ( = 24) was separated into three groups: the group without treatment ( = 8), the group with sham stimulation ( = 8), and the group with VNS treatment ( = 8). VNS was delivered for 30 min per day for 6 weeks after the establishment of NAFLD using a digital TENS device. The subsequent assessments included hepatic triglyceride, cholesterol content, serum lipid profile, and liver function testing. In this context, inflammatory biomarkers (TNF-α, IL-6) and hepatic oxidative stress (MDA, SOD, and GPx) were also assessed. To clarify the possible mechanisms behind the protective benefits of VNS, additional histological inspection and immunohistochemistry analysis of TNF-α and Caspase-3 were performed. In the NAFLD-affected obese rats, VNS markedly decreased the rats' body mass index (BMI) and abdominal circumference (AC). Liver function markers (albumin, ALT, and AST) and the serum lipid profile-which included a notable decrease in the amounts of hepatic triglycerides and cholesterol-were both markedly improved. Additionally, oxidative stress and inflammatory indicators showed a considerable decline with VNS. Notably, the liver tissues examined by histopathologists revealed that there is evidence of the protective impact of VNS on the oxidative and inflammatory states linked to HFD-induced NAFLD while maintaining the architectural and functional condition of the liver. Our findings suggest that VNS may represent a promising therapeutic candidate for managing NAFLD induced by obesity. It can be considered to be an effective adjuvant physiological intervention for the obese population with NAFLD to spare the liver against obesity-induced deleterious injury.